Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRME
- Price
- 1.33
- Stock movement up
- +0.16 (13.68%)
- Company name
- Prime Medicine, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 174.44M
- Ent value
- 199.75M
- Price/Sales
- 2.71
- Price/Book
- 0.92
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -77.42%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PRME does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.71 |
| Price to Book | 0.92 |
| EV to Sales | 3.11 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 131.16M |
| EPS (TTM) | -1.83 |
| FCF per share (TTM) | -1.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 64.27M |
| Gross profit (TTM) | 61.70M |
| Operating income (TTM) | -226.29M |
| Net income (TTM) | -219.25M |
| EPS (TTM) | -1.83 |
| EPS (1y forward) | -1.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.01% |
| Operating margin (TTM) | -352.11% |
| Profit margin (TTM) | -341.16% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 117.98M |
| Net receivables | 0.00 |
| Total current assets | 246.07M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 84.53M |
| Total assets | 332.78M |
| Accounts payable | 5.43M |
| Short/Current long term debt | 41.25M |
| Total current liabilities | 37.88M |
| Total liabilities | 143.28M |
| Shareholder's equity | 189.50M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -182.97M |
| Capital expenditures (TTM) | 7.34M |
| Free cash flow (TTM) | -190.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -115.70% |
| Return on Assets | -65.88% |
| Return on Invested Capital | -113.02% |
| Cash Return on Invested Capital | -98.11% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.18 |
| Daily high | 1.33 |
| Daily low | 1.16 |
| Daily Volume | 1.76M |
| All-time high | 21.12 |
| 1y analyst estimate | 13.09 |
| Beta | 2.09 |
| EPS (TTM) | -1.83 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PRME | S&P500 | |
| Current price drop from All-time high | -93.70% | -12.89% |
| Highest price drop | -94.55% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -57.03% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 613 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
174.44M
Marketcap category
Small-cap
Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Employees
234
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page